Abstracts tagged "safety and therapy"

Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort
Emanuele Calabresi¹, Simone Barsotti², Elisa Cioffi³, Alessandra Tripoli¹, Andrea Delle Sedie¹, Laura Bazzichi⁴, Ornella Mazzarella¹, Rossella Neri⁴ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
Abstract Number: 3180 • 2015 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Treatment in Juvenile Idiopathic Arthritis: A Pilot Study
Joost Swart¹, Nico Wulffraat², Berent J. Prakken³, Ineke Slaper-Cortenbach⁴ and Caroline Lindemans⁵, ¹PO Box 85090, UMC Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center, Utrecht, Netherlands, ⁴Cell Therapy Facility, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a frequent childhood disease with a prevalence of 1 per 1000 children. The introduction of the biological agents including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].